• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

小型综述:骨保护素/核因子κB受体活化因子配体/核因子κB受体活化因子系统

Minireview: the OPG/RANKL/RANK system.

作者信息

Khosla S

机构信息

Endocrine Research Unit, Division of Endocrinology, Metabolism, and Nutrition, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA.

出版信息

Endocrinology. 2001 Dec;142(12):5050-5. doi: 10.1210/endo.142.12.8536.

DOI:10.1210/endo.142.12.8536
PMID:11713196
Abstract

The identification of the OPG/RANKL/RANK system as the dominant, final mediator of osteoclastogenesis represents a major advance in bone biology. It ended a long-standing search for the specific factor produced by preosteoblastic/stromal cells that was both necessary and sufficient for osteoclast development. The initial cloning and characterization of OPG as a soluble, decoy receptor belonging to the TNF receptor superfamily was the first step that eventually led to an unraveling of this system. Soon thereafter, the molecule blocked by OPG, initially called OPG-ligand/osteoclast differentiating factor (ODF) and subsequently RANKL, was identified as the key mediator of osteoclastogenesis in both a membrane-bound form expressed on preosteoblastic/stromal cells as well as a soluble form. RANKL, in turn, was shown to bind its receptor, RANK, on osteoclast lineage cells. The decisive role played by these factors in regulating bone metabolism was demonstrated by the findings of extremes of skeletal phenotypes (osteoporosis vs. osteopetrosis) in mice with altered expression of these molecules. Over the past several years, work has focused on identifying the factors regulating this system, the signaling mechanisms involved in the RANKL/RANK pathway, and finally, potential alterations in this system in metabolic bone disorders, from the extremely common (i.e. postmenopausal osteoporosis) to the rare (i.e. familial expansile osteolysis).

摘要

骨保护素(OPG)/核因子κB受体活化因子配体(RANKL)/核因子κB受体活化因子(RANK)系统被确定为破骨细胞生成的主要、最终介质,这代表了骨生物学的一项重大进展。它结束了对成骨前体细胞/基质细胞产生的、对破骨细胞发育既必要又充分的特定因子的长期探索。最初将OPG克隆并鉴定为属于肿瘤坏死因子受体超家族的可溶性诱饵受体,这是最终揭示该系统的第一步。此后不久,被OPG阻断的分子,最初称为OPG配体/破骨细胞分化因子(ODF),随后称为RANKL,被确定为破骨细胞生成的关键介质,它以在成骨前体细胞/基质细胞上表达的膜结合形式以及可溶性形式存在。反过来,RANKL被证明能与破骨细胞谱系细胞上的受体RANK结合。这些分子表达改变的小鼠出现极端骨骼表型(骨质疏松症与骨质石化症)的研究结果证明了这些因子在调节骨代谢中所起的决定性作用。在过去几年中,研究工作集中在确定调节该系统的因子、RANKL/RANK途径中涉及的信号传导机制,以及最终,从极为常见的(即绝经后骨质疏松症)到罕见的(即家族性膨胀性骨溶解症)代谢性骨病中该系统的潜在改变。

相似文献

1
Minireview: the OPG/RANKL/RANK system.小型综述:骨保护素/核因子κB受体活化因子配体/核因子κB受体活化因子系统
Endocrinology. 2001 Dec;142(12):5050-5. doi: 10.1210/endo.142.12.8536.
2
Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.白细胞介素-6与前列腺素E2信号系统之间的相互作用,通过影响骨保护素/核因子-κB受体激活因子配体(RANKL)/核因子-κB受体激活因子(RANK)系统,导致破骨细胞生成增强。
Endocrinology. 2005 Apr;146(4):1991-8. doi: 10.1210/en.2004-1167. Epub 2004 Dec 23.
3
Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption.骨保护素及其配体:破骨细胞生成与骨吸收调控的新范式。
Osteoporos Int. 2000;11(11):905-13. doi: 10.1007/s001980070028.
4
Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.骨保护素及其配体:破骨细胞生成与骨吸收调控的新范式。
Medscape Womens Health. 2000 Mar;5(2):5.
5
The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.骨保护素和骨保护素配体在骨吸收旁分泌调节中的作用。
J Bone Miner Res. 2000 Jan;15(1):2-12. doi: 10.1359/jbmr.2000.15.1.2.
6
Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment.循环骨保护素与核因子κB受体活化因子配体:在代谢性骨病评估中的临床应用
J Clin Endocrinol Metab. 2005 Nov;90(11):6323-31. doi: 10.1210/jc.2005-0794. Epub 2005 Aug 16.
7
[Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis].[破骨细胞生成抑制因子(OCIF)/骨保护素(OPG)作为骨质疏松症的新型治疗药物]
Clin Calcium. 2005 Jan;15(1):35-42.
8
Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system.白细胞介素-6与前列腺素E2通过骨保护素/核因子κB受体活化因子配体/核因子κB受体活化因子系统对破骨细胞生成的交互作用。
Ann N Y Acad Sci. 2006 Apr;1068:225-33. doi: 10.1196/annals.1346.047.
9
Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis.核因子κB受体激活剂配体/破骨细胞分化因子在类风湿关节炎滑膜细胞破骨细胞生成中的作用。
Arthritis Rheum. 2000 Feb;43(2):259-69. doi: 10.1002/1529-0131(200002)43:2<259::AID-ANR4>3.0.CO;2-W.
10
Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.肿瘤坏死因子受体和配体家族新成员对破骨细胞分化和功能的调节
Endocr Rev. 1999 Jun;20(3):345-57. doi: 10.1210/edrv.20.3.0367.

引用本文的文献

1
Dietary cholecalciferol and 25-hydroxyvitamin D supplementation improved eggshell and bone quality of laying ducks during 60 to 76 weeks of age.在60至76周龄期间,日粮补充胆钙化醇和25-羟基维生素D可改善蛋鸭的蛋壳和骨骼质量。
Anim Nutr. 2025 Jun 20;22:414-425. doi: 10.1016/j.aninu.2025.02.011. eCollection 2025 Sep.
2
Global epidemiology and burden of osteoporosis among postmenopausal women: insights from the Global Burden of Disease Study 2021.绝经后女性骨质疏松症的全球流行病学及负担:来自《2021年全球疾病负担研究》的见解
NPJ Aging. 2025 Sep 1;11(1):78. doi: 10.1038/s41514-025-00269-2.
3
Genistein in the Prevention and Treatment of Periodontitis: A Review.
染料木黄酮在牙周炎防治中的研究综述
Food Sci Nutr. 2025 Aug 4;13(8):e70657. doi: 10.1002/fsn3.70657. eCollection 2025 Aug.
4
Effects of orthodontic tooth movement on periodontal tissues after ligature-induced periodontitis through the mechanism of RANKL-induced osteoclastogenesis: an animal study.通过RANKL诱导破骨细胞生成机制,结扎诱导性牙周炎后正畸牙齿移动对牙周组织的影响:一项动物研究。
BMC Oral Health. 2025 Jul 30;25(1):1278. doi: 10.1186/s12903-025-06627-6.
5
Sending the Signal to Bone: How Tumor-Derived EVs Orchestrate Pre-Metastatic Niche Formation and Skeletal Colonization.向骨骼发送信号:肿瘤衍生的细胞外囊泡如何协调前转移微环境的形成和骨骼定植
Biomedicines. 2025 Jul 4;13(7):1640. doi: 10.3390/biomedicines13071640.
6
Extracellular Vesicles From Prostate Cancer-Corrupted Osteoclasts Drive a Chain Reaction of Inflammatory Osteolysis and Tumour Progression at the Bone Metastatic Site.来自前列腺癌破坏的破骨细胞的细胞外囊泡驱动骨转移部位的炎症性骨溶解和肿瘤进展的连锁反应。
J Extracell Vesicles. 2025 Jun;14(6):e70091. doi: 10.1002/jev2.70091.
7
Osteoimmunology: Crosstalk Between T Cells and Osteoclasts in Osteoporosis.骨免疫学:骨质疏松症中T细胞与破骨细胞之间的相互作用
Clin Rev Allergy Immunol. 2025 Apr 10;68(1):41. doi: 10.1007/s12016-025-09046-1.
8
Bone in Parathyroid Diseases Revisited: Evidence From Epidemiological, Surgical and New Drug Outcomes.再探甲状旁腺疾病中的骨:来自流行病学、手术及新药疗效的证据
Endocr Rev. 2025 Jul 15;46(4):576-620. doi: 10.1210/endrev/bnaf010.
9
Osteoclastogenesis in Patients With Systemic Sclerosis With and Without Calcinosis Cutis.伴有和不伴有皮肤钙化的系统性硬化症患者的破骨细胞生成
ACR Open Rheumatol. 2025 Apr;7(4):e70029. doi: 10.1002/acr2.70029.
10
Molecular mechanisms underlying the effects of statins on bone metabolism: an evolving paradigm of statins delivery modalities for bone regeneration.他汀类药物对骨代谢影响的分子机制:骨再生中他汀类药物递送方式的不断演变模式。
Pharmacol Rep. 2025 Jun;77(3):624-644. doi: 10.1007/s43440-025-00716-7. Epub 2025 Apr 1.